SABS · SAB Biotherapeutics, Inc.
$3.78
+0.08 (+2.16%)
At close · Aug 21
Market Cap
$343.93M
Shares
90.99M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.78
Open$3.74
Day$3.70–3.83
52W close$1.95–4.59
Avg vol 30d439K
Short int4.7M · 5.1% float · 9.0d
Short vol69%
Last earningsAug 6, 2026
DataJan 2024–Aug 2026
Filing10-Q · Aug 6
Raw chart and full-history price indicators begin at the captured split on Jan 5, 2024; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−0%
below
Price vs 50-day avg
+1%
above
RSI (14)
53
neutral
MACD trend
Positive
52-week position
69%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+8%
trailing
6-month return
−7%
trailing
YTD return
+1%
this year
Relative strength
−19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+11% holders QoQ · +29 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.12% of float · ▲ +6.5% MoM · 9.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
92 holders — near 3-yr high, broad support
Squeeze score
65
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+79%
Y/Y
Free cash flow
$-45.7M
Balance sheet
$10.2M
net cash
Quant / Vol
risk profile
Volatility
71%
annualized · 1-yr
Max drawdown
−30%
past year
ATR
4.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−0%
Neutral
Price vs 50-day avg
+1%
Bullish
RSI (14)
53
Neutral
MACD trend
Positive
Bullish
52-week position
69%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+11% holders QoQ · +29 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.12% of float · ▲ +6.5% MoM · 9.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
92 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $4 · 69%
Range high $5
vs 200-day avg 0%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SABS
this stock
SAB Biotherapeutics, Inc.
|
$343.93M | +1.1% | -100.0% | — | 5.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Jan 5, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SABS | +2.2% | +7.7% | -7.1% | +5.9% | +1.1% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +3.5% | +4.1% | -18.7% | +3.4% | -11.2% |
Key facts
CIK
1833214
CUSIP
78397T202
13F (30d)
97 filings
90 filers
Visit website
Investor relations